Melinda Cook, PharmD, BCOP

Explore how combining BTK inhibitors with CAR T-cell therapy enhances treatment efficacy for B-cell malignancies while managing potential toxicities.

Axatilimab is a colony-stimulating factor-1 receptor–blocking monoclonal antibody indicated after 2 lines of systemic therapy.